Elicio Therapeutics (ELTX) EBT (2020 - 2026)

Elicio Therapeutics (ELTX) has reported EBT for 7 consecutive years, with -$10.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 5.77% year-over-year to -$10.7 million; the trailing twelve-month figure through Jun 2026 stood at -$39.0 million (up 12.99% YoY), and the FY2025 full-year result was -$38.8 million, up 14.51% from the prior year.
• EBT advanced to -$10.7 million in Q2 2026 per ELTX's latest filing, from -$10.9 million in the prior quarter.
• Across five years, EBT topped out at -$6.0 million in Q4 2022 and bottomed at -$14.5 million in Q1 2022.
• Historically, EBT has averaged -$9.8 million across 5 years, with a median of -$10.1 million in 2024.
• The widest YoY moves for EBT: up 59.99% in 2022, down 140.99% in 2022.
• Over 5 years, EBT stood at -$6.0 million in 2022, then sank by 55.37% to -$9.3 million in 2023, then plunged by 47.12% to -$13.7 million in 2024, then soared by 33.05% to -$9.2 million in 2025, then fell by 16.58% to -$10.7 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$10.7 million, -$10.9 million, and -$9.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.